Olaparib
Olaparib (AZD2281; KU0059436) is a potent and orally active PARP inhibitor with IC50s of 5 and 1 nM for PARP1 and PARP2, respectively. Olaparib is an autophagy and mitophagy activator[1][2][3][4].
Product Specifications
CAS Number
763113-22-0
Product Name Alternative
AZD2281; KU0059436
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Autophagy; Mitophagy; PARP
Type
Reference compound
Related Pathways
Autophagy; Cell Cycle/DNA Damage; Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/Olaparib.html
Purity
99.98
Solubility
DMSO : 100 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=C(C1=CC(CC(C2=C3C=CC=C2)=NNC3=O)=CC=C1F)N4CCN(C(C5CC5)=O)CC4
Molecular Formula
C24H23FN4O3
Molecular Weight
434.46
Precautions
H302, H315, H319, H335
References & Citations
[1]Menear KA, et al. 4-[3- (4-cyclopropanecarbonylpiperazine-1-carbonyl) -4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly (ADP-ribose) polymerase-1. J Med Chem. 2008 Oct 23;51 (20) :6581-91|[2]Senra JM, et al. Inhibition of PARP-1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft.Mol Cancer Ther. 2011 Oct;10 (10) :1949-58.|[3]Yasukawa M, et al. Synergetic Effects of PARP Inhibitor AZD2281 in Oral Squamous Cell Carcinoma in Vitro and in Vivo. Int J Mol Sci. 2016 Feb 24;17 (3) :272.|[4]Bian X, et al. PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy. Oncogene. 2018 Jan 18;37 (3) :341-351.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
PARP1; PARP2; TNKS1/PARP5A
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
AC-15-13-10 0.5 mL
Anti-Rat IgG (H+L), Mouse Serum Absorbed - 15nm Gold Conjugate
Sign In for Pricing
View Details 